CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 61 enrolled
Drug / intervention
Carboplatin +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03141359
NCT03141359Phase 2Active

LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer

Wake Forest University Health Sciences·interventional·Posted May 5, 2017·Updated Feb 5, 2026

In Brief

A Phase 2 clinical trial evaluating SBRT, Carboplatin, and 5 other interventions for Lung Cancer Stage II and 2 related conditions. Active but no longer recruiting, targeting 61 participants across 1 site.

Detailed Summary

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation with or without consolidation chemotherapy. A total of 60 subjects will be enrolled to this study over a 4 year accrual period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2Active
2018201920202021202220232024202520262027
First PostedMay 5, 2017
Enrollment StartMay 12, 2017
Primary CompletionJul 12, 2023
Study CompletionJul 1, 2027
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 9.2 years ago

Interventions

SBRTradiation

Primary tumor SBRT

Carboplatindrug

concurrent chemotherapy

Paclitaxeldrug

concurrent chemotherapy

cis Platinumdrug

concurrent chemotherapy

Etoposidedrug

concurrent chemotherapy

IMRTradiation

mediastinal radiation

Durvalumabdrug

adjuvant immunotherapy